$0.02
(2.71%)
Add to watchlist
Create an alert
Stocks and Shares ISA
Fund and Share AccountAvenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.
Company Information
About this company
Key people
Alexandra Maclean
Chief Executive Officer, Director
David Jin
Interim Chief Financial Officer, Chief Operating Officer
Jay D. Kranzler
Non-Executive Chairman of the Board
Lindsay A. Rosenwald
Director
Faith L. Charles
Independent Director
Neil Herskowitz
Independent Director
Curtis Gale Oltmans
Independent Director
Click to see more
Key facts
- Shares in issue3.18m
- EPICATXI
- ISINUS05360L4032
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$2.23m
- Employees2
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.